Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | SDCBP | O00560 | 1/20 | 0.51 |
| ▸ | SDC2 | P34741 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754096 | 1.00 | CTSK (0.51) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL9980711 | 0.89 | KMT2A (0.45) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL8903579 | 0.88 | CTSS (0.53) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL30029784 | 0.88 | CTSK (0.48) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL1057086 | 0.87 | CTSS (0.54) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL25652880 | 0.86 | KLK5 (0.50) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL16667727 | 0.86 | KLK5 (0.50) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL23629905 | 0.86 | CTSS (0.51) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL23629908 | 0.86 | CTSS (0.51) | CTSKCTSSSDCBPSDC2KMT2A | |
| SCHEMBL27383483 | 0.85 | CTSS (0.57) | CTSKCTSSSDCBPSDC2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174569-A1 | PROCESS PER PREPARING (3a,5a)-20-OXOPREGNAN-3-YL GLYCYL-L-VALINATE HYDROCHLORIDE | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-06-08 | — | — | US | claimed |
| EP-3050563-B1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2018-05-09 | — | — | EP | claimed |
| EP-2616067-B1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2016-05-18 | — | — | EP | claimed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| CN-113999237-B | Nucleoside prodrug and application thereof | 润佳（苏州）医药科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230174569-A1 | PROCESS PER PREPARING (3a,5a)-20-OXOPREGNAN-3-YL GLYCYL-L-VALINATE HYDROCHLORIDE | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-06-08 | — | — | US | disclosed |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| CN-113999237-A | Nucleoside prodrug and application thereof | 润佳（苏州）医药科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-20200339615-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| WO-2020215156-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020130152-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-25 | — | — | WO | disclosed |
| US-10508111-B2 | 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-B]pyridin-3-yl]-nicotinonitrile derivatives and their use as IRAK inhibitors | GALAPAGOS NV (BE) | 2019-12-17 | — | — | US | disclosed |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20180305351-A1 | 6-[5-AMINO-6-(2-ETHOXYETHOXY)-IMIDAZO[4,5-B]PYRIDIN-3-YL]-NICOTINONITRILE DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | GALAPAGOS NV (BE) | 2018-10-25 | — | — | US | disclosed |
| CN-101928326-B | Substitution five-heterocyclic alkyl aminoacyl compound and application thereof | INST PHARM & TOXICOLOGY AMMS | 2015-07-08 | — | — | CN | disclosed |
| CN-101928326-A | Substitution five-heterocyclic alkyl aminoacyl compound and application thereof | INST PHARM & TOXICOLOGY AMMS | 2010-12-29 | — | — | CN | disclosed |
| EP-1911762-A1 | Amino alcohols and their use as renin inhibitors | Speedel Experimenta AG (CH) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | C5AR2, C5AR1, C3AR1 | CTSK 1208/4885CTSS 910/4885SDCBP 3347/4885 |
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | CTSK 1548/4885CTSS 2458/4885SDCBP 4488/4885 |
| US-20230174569-A1 | PROCESS PER PREPARING (3a,5a)-20-OXOPREGNAN-3-YL GLYCYL-L-VALINATE HYDROCHLORIDE | CYP3A5, CYP17A1, UGT1A3 | CTSK 3189/4885CTSS 3465/4885SDCBP 4514/4885 |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | CTSK 1548/4885CTSS 2458/4885SDCBP 4488/4885 |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | CTSK 1208/4885CTSS 910/4885SDCBP 3347/4885 |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | CTSK 1548/4885CTSS 2458/4885SDCBP 4488/4885 |
| US-10508111-B2 | 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-B]pyridin-3-yl]-nicotinonitrile derivatives and their use as IRAK inhibitors | IRAK1, IRAK2, IRAK3 | CTSK 3574/4885CTSS 4327/4885SDCBP 3795/4885 |
| US-20180305351-A1 | 6-[5-AMINO-6-(2-ETHOXYETHOXY)-IMIDAZO[4,5-B]PYRIDIN-3-YL]-NICOTINONITRILE DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | IRAK1, IRAK2, IRAK3 | CTSK 3574/4885CTSS 4327/4885SDCBP 3795/4885 |
| US-20200339615-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | CTSK 1548/4885CTSS 2458/4885SDCBP 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.